Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

L. Locke, Frederick; M. Rossi, John; S. Neelapu, Sattva; A. Jacobson, Caron; B. Miklos, David; Ghobadi, Armin; O. Oluwole, Olalekan; M. Reagan, Patrick; J. Lekakis, Lazaros; Lin, Yi; Sherman, Marika; Better, Marc; Y. Go, William; S. Wiezorek, Jeffrey; Xue, Allen; Bot, Adrian

doi:10.1182/bloodadvances.2020002394

Public

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Published in Blood Advances • Oct 9, 2020

Authors:

Frederick L. Locke

John M. Rossi

Sattva S. Neelapu

Abstract

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for sec...

Subject

Medicine

Oncology

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!